Figure 1.

The concept of dynamic ligation screening (DLS). Substrate 1 competes with peptide aldehyde inhibitor 2 for the SARS‐CoV main protease (blue). Active fragment 3 leads to an increased inhibition through the binding of the imine ligation product to the active site.